Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Koller, L; Kleber, ME; Brandenburg, VM; Goliasch, G; Richter, B; Sulzgruber, P; Scharnagl, H; Silbernagel, G; Grammer, TB; Delgado, G; Tomaschitz, A; Pilz, S; Berger, R; Mörtl, D; Hülsmann, M; Pacher, R; März, W; Niessner, A.
Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction.
Circ Heart Fail. 2015; 8(6):1059-1067
Doi: 10.1161/CIRCHEARTFAILURE.115.002341
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- März Winfried
- Pilz Stefan
- Scharnagl Hubert
- Silbernagel Günther
- Tomaschitz Andreas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Strategies to improve risk prediction are of major importance in patients with heart failure (HF). Fibroblast growth factor 23 (FGF-23) is an endocrine regulator of phosphate and vitamin D homeostasis associated with an increased cardiovascular risk. We aimed to assess the prognostic effect of FGF-23 on mortality in HF patients with a particular focus on differences between patients with HF with preserved ejection fraction and patients with HF with reduced ejection fraction (HFrEF). FGF-23 levels were measured in 980 patients with HF enrolled in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study including 511 patients with HFrEF and 469 patients with HF with preserved ejection fraction and a median follow-up time of 8.6 years. FGF-23 was additionally measured in a second cohort comprising 320 patients with advanced HFrEF. FGF-23 was independently associated with mortality with an adjusted hazard ratio per 1-SD increase of 1.30 (95% confidence interval, 1.14-1.48; P<0.001) in patients with HFrEF, whereas no such association was found in patients with HF with preserved ejection fraction (for interaction, P=0.043). External validation confirmed the significant association with mortality with an adjusted hazard ratio per 1 SD of 1.23 (95% confidence interval, 1.02-1.60; P=0.027). FGF-23 demonstrated an increased discriminatory power for mortality in addition to N-terminal pro-B-type natriuretic peptide (C-statistic: 0.59 versus 0.63) and an improvement in net reclassification index (39.6%; P<0.001). FGF-23 is independently associated with an increased risk of mortality in patients with HFrEF but not in those with HF with preserved ejection fraction, suggesting a different pathophysiologic role for both entities. © 2015 American Heart Association, Inc.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged, 80 and over -
- Biomarkers - blood
- Cohort Studies -
- Female -
- Fibroblast Growth Factors - blood
- Heart Failure - blood Heart Failure - mortality Heart Failure - physiopathology
- Humans -
- Male -
- Middle Aged -
- Natriuretic Peptide, Brain - blood
- Peptide Fragments - blood
- Predictive Value of Tests -
- Risk Factors -
- Stroke Volume - physiology
- Survival Analysis -
- Find related publications in this database (Keywords)
- biological markers
- fibroblast growth factors
- heart failure
- mortality
- risk assessment